Status:
TERMINATED
Innate Immune Response During Community Acquired Pneumonia
Lead Sponsor:
University Hospital, Tours
Conditions:
Community-acquired Pneumonia
Acute Respiratory Distress Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Community acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Despite recent improvement in acute management (specifically for administration of antibiotics) many severe pr...
Detailed Description
\- Clinical and scientific background: Community acquired pneumonia is a major cause of morbidity and mortality worldwide. Despite recent improvement in acute management (specifically for administrat...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- "Pneumonia" group:
- Admission to the Intensive Care Units or Pneumonia service of Tours University Hospital or Intensive Care Unit or Limoges University Hospital
- Initial diagnosis of acute community-acquired pneumonia suggested by the presence of a cough, dirty sputum, chest pain and / or dyspnea (at least two criteria required), associated with the presence of a radiological or CT infiltrate initially
- Patient for whom it is not envisaged, a priori, to limit treatment within 5 days following inclusion, for ethical reasons, due to age and advanced comorbidities, and / or a level of severity beyond all therapeutic possibilities.
- Diagnosis of pneumonia done within 48 hours after admission to the hospital
- Participant admitted to the hospital for less than 8 days
- "Control" group:
- Admission to the Intensive Care Units of the University Hospital of Tours or Limoges University Hospital
- Use of invasive mechanical ventilation for less than 48 hours
- Predictable duration of invasive mechanical ventilation\> 48h
- Participant admitted to the hospital for less than 8 days
- Absence of pneumonia criteria (according to the criteria defined for the "Pneumonia" participant group)
- Absence shock (defined by the need for vasopressor despite volume expansion ≥30mL/kg, associated with a blood lactate level ≥ 2mmol / L
- Patient for whom it is not envisaged, a priori, to limit treatment within 5 days following inclusion, for ethical reasons, due to age and advanced comorbidities, and / or a level of severity beyond all therapeutic possibilities.
- Exclusion Criteria:
- Participant under protection
- Pregnant or lactating women
Exclusion
Key Trial Info
Start Date :
January 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 4 2025
Estimated Enrollment :
258 Patients enrolled
Trial Details
Trial ID
NCT03379207
Start Date
January 10 2018
End Date
June 4 2025
Last Update
November 24 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitakl of TOURS Département of Pneumonia
Tours, France, 37044
2
University Hospital -Bretonneau - Intensive Care
Tours, France, 37044
3
University Hospital of Tours; INSERM CIC 1415
Tours, France, 37044